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Classical Hodgkin lymphoma (CHL) is a relatively uncommon B cell-derived neoplasm that presents with rare malignant cells
in an abundant reactive background. The diagnosis of CHL currently relies on a combination of morphologic ﬁndings and
immunohistochemicalstains.Withtheexceptionofrarecaseswithdramaticallyincreasedmalignantpopulations,isolationofpure
viable tumor cells has not been historically possible. Recently, a reliable ﬂow cytometric assay for direct detection and isolation of
the malignant cells in this disease has been developed. This assay has proven useful diagnostically and has been clinically validated
to have a very high sensitivity and nearly absolute speciﬁcity for the diagnosis of CHL in routine clinical samples. This paper
describes the methodology for the ﬂow cytometric detection of CHL in clinical samples as well as current state of evaluation of
background lymphocytes as an adjunct diagnostic test. Also discussed are exciting research applications of the direct isolation
of viable tumor cells in CHL. The current state of ﬂow cytometric evaluation of nodular lymphocyte predominant Hodgkin
lymphoma and T cell-rich large B cell lymphoma is also brieﬂy discussed.
1.ClinicalDiagnosisofClassicalHodgkin
Lymphoma by Flow Cytometry
With increasingly rare exceptions, diagnosis of lympho-
proliferative diseases and myeloid stem cell disorders
relies on a multimodal analysis in which ﬂow cytometry
plays a signiﬁcant role [1]. While a detailed technical
overview of ﬂow cytometry is beyond the scope of this
paper and can be found elsewhere [1], ﬂow cytometry
immunophenotyping relies on the detection of individual
cells in liquid phase by using antigen expression and
their light scatter properties. The antibody-stained cells
are characterized by detecting signals from antibody-linked
laser-activated ﬂuorescent tags. By using combinations of
antibody-linkedtagswithdistinctexcitationand/oremission
spectra, a single cell can be interrogated for the presence
and intensity of expression of multiple antigens. Newer
digital acquisition multilaser ﬂow cytometers allow for rapid
detection of millions of individual cells with simultaneous
evaluation of ten or more antigens in a single analy-
sis.
Therelativelyrapidanalyticaltimemakesﬂowcytometry
an attractive initial diagnostic modality. This analysis can
guide further morphologic and molecular workup leading
to savings in cost and time of the total evaluation. In many
cases, the immunophenotype obtained by ﬂow cytometry
alone can be diagnostic for speciﬁc hematologic neoplasms
in a correct clinical and morphologic context. Because of the
ability to analyze a large number of cells, ﬂow cytometry is
ideally suited for the detection of relatively rare, antigenically
distinct populations within complex cell mixtures. This abil-
ity has been successfully exploited clinically for the detection
of relatively low levels of minimal residual disease (MRD)
posttreatment in leukemia and multiple myeloma is now
considered one of the critical modalities to monitor MRD
[1–4]. It also appears to be ideally suited for the detection
of lymphomas where the malignant population is relatively
rare, and most of the cells belong to a benign inﬂammatory
background. Examples of such disorders include classical
Hodgkin lymphoma (CHL), nodular lymphocyte predomi-
nant Hodgkin lymphoma (NLPHL), and T cell-rich large B
cell lymphoma (TCRLBCL).2 Advances in Hematology
Classical Hodgkin lymphoma is a B cell neoplasm where
the neoplastic population represents less than 1% and
frequently less than 0.01% of the total cells [5]. The
neoplastic population, referred to as Hodgkin or Reed-
Sternberg (HRS) cells, can often be recognized morpho-
logically by large cell size, sometimes multilobated nuclei,
and characteristically prominent nucleoli. Until recently, the
diagnosis relied exclusively on the morphologic appearance
of the tumor in ﬁxed paraﬃn-embedded tissue sections.
The development of the technique to stain cells in tissue
sections with antibody (immunohistochemistry) has added
signiﬁcantlytothespeciﬁcityofthediagnosisandallowedfor
furthertissue-basedanalysisoftheimmunophenotype ofthe
HRS cells. Over the past twenty years or so, immunohisto-
chemical studies have uncovered numerous surface antigens
for the reliable detection of HRS cells in tissue sections.
Among these, expression of CD30 and CD15 combined with
lack of expression of CD20 (the B cell antigen), CD45 (pan-
hematopoietic antigen), and CD3 (T cell antigen) are used in
clinical practice [5].Additionally, bright CD40 [6] andCD95
[7] expression has been demonstrated in a great majority
of CHL cases and could potentially help to distinguish HRS
cells from other CD30 positive events in the proper context.
Yet, detection of HRS cells by ﬂow cytometry has remained
unobtainable.
2.Technical Aspect and Remaining Challenges
inClinicalDetection ofHRSCellsby
FlowCytometry
The inability to detect the HRS cells had often been
attributed to their cell lysis during preparations or during
the cell acquisition [8]. As later experience has shown, these
problems have been overstated. Other signiﬁcant challenges
were indeed present, including the relative rarity of the HRS
cells within CHL tumors, rosetting of the neoplastic cells
by T cells in cell preparations of CHL biopsies, and the
large size of the HRS cells. Recently, a method that allows a
routinedetectionofHRScellswithnearlyabsolutespeciﬁcity
and high sensitivity for clinical diagnosis of CHL has been
developed [9, 10]. This section describes how problems that
arose with earlier detection methods have been overcome
using newer analytic and cell preparation approaches.
Normal T cells have been shown to closely associate
with HRS cells in immunohistochemical sections and bind
(rosette) cell lines derived from CHL tumors. Indeed, using
a CHL cell line (L428), Sanders and coworkers have shown
that high levels of CD54 (ICAM-1) and CD58 (LFA-3) on
the HRS cell bind to LFA-1 and CD2 on the T cell [11]. This
phenomenoncanbeseenonthecytospinsoftheroutineﬂow
cytometric cell suspensions of CHL tumors (see Figure 1).
This rosetting causes a signiﬁcant proportion of HRS
cells to fall outside the area that is usually used for recog-
nition of individual (nonaggregated) cells in ﬂow cytometric
analysis. The HRS-T cell rosettes fall either in the area that
is routinely excluded as coincident events (cell aggregates)
or are located at the very edge or beyond the high end
of the measurable range of forward scatter parameters set
to analyze hematopoietic cells. Moreover, the interaction of
HRS cells with the T cells is expected to lead to a composite
immunophenotype between these two cell types. Indeed,
most cases of CHL cells do demonstrate a composite, HRS-
Tcellimmunophenotype (CD15+,CD30+,CD40+, CD95+,
CD20−,CD3+,CD5+,andCD45+).Disruptinginteractions
between HRS cells and T cells with blocking antibodies
reduces rosetting by T cells leading to the expected HRS
cell immunophenotype (CD15+, CD30+, CD40+, CD95+,
CD20−,C D 3 −,C D 5 −, and CD45 dim). In routine clinical
practice, blocking antibodies are not necessary with most
CHL cases demonstrating both rosetted and unrosetted HRS
population. Furthermore, this unique feature of Hodgkin
lymphomas can be diagnostically useful (Figure 2).
Further development of a reliable method of diagnosis
of classical Hodgkin lymphoma by ﬂow cytometry has
beneﬁted from the advances in the instrumentation. Intro-
duction of rapid digital event acquisition on the modern
cytometers now allows for the routine analysis of 500,000
events or more within less than 5 minutes, bringing a
population that represents 0.01% of the total white cells
well within range of sensitivity of clinical cytometry. In
addition, increased numbers of lasers and detectors on the
modern instruments allow for simultaneous interrogation of
10 or more antigens within the same tube. This, in turn,
increases conﬁdence in identiﬁcation of small populations
based on multidimensional analysis of multiple antibody
staining patterns on single cells [12]. In our practice, using
a nine-antibody combination in a single tube (currently
CD5-ECD,CD15-APC,CD20-PE-Cy7,CD30-PE,CD40-PE-
Cy5.5, CD45-APC-H7, CD64-FITC, CD71-APC-A700, and
CD95-PB) allows for detection of cases with a relatively low
abundance of HRS cells even with some deviation from
the canonical CD30 and CD15 bright immunophenotype
[9, 10]. Such detection relies on stepwise exclusion of
reactive populations (CD20-positive B cells, CD5-positive
T cells, and CD64-positive monocytes and granulocytes)
and reﬁnement of the population of interest with the
most common immunophenotype of CD15 (intermediate
to bright), CD30 (intermediate to bright), CD40 (bright),
CD71 (bright), and CD95 (bright) in multiple projections.
Figure 3 demonstrates the usage of this strategy to detect
a relatively small malignant population in a CHL lymph
node.
In a recent blinded single-center clinical validation study
that included common morphologic and immunopheno-
typic mimics of CHL, the above ﬂow cytometry reagent
combination demonstrated an 88.7% sensitivity and 100%
speciﬁcity for diagnosing CHL. Interestingly, many false
negative cases were greater than 72 hours in age, possibly
suggesting selective loss of HRS cells during prolonged
sample storage [10] .W h i l ew eh a v en o ts p e c i ﬁ c a l l ya n a l y z e d
the diagnostic sensitivity of diﬀerent sample types, very
paucicellular samples from small biopsies and ﬁne needle
aspirations (FNA) may not have similar sensitivity. Our
study speciﬁcally excluded samples that contained less than
50,000 viable cells due to the expected frequency of HRS cells
being lower than the cutoﬀ required for deﬁnite abnormal
population identiﬁcation.Advances in Hematology 3
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Figure 1:Wright-Giemsa-stainedcytomorphologyofrepresentative,intactﬂowcytometriccell-sortedHRScellsfromlymphnodesinvolved
by CHL with immunophenotypes consistent with CHL. (a) A CHL case ﬂow sorted in absence of blocking antibodies showing the presence
of T cell-HRS cell rosettes. (b) The same case as seen in (a) (above) where ﬂow sorted in the presence of blocking antibodies showing
only isolated HRS cells, suggesting the blocking antibodies disrupted the rosettes. (c) A CHL case ﬂow sorted in the presence of blocking
antibodies. (d) A CHL case ﬂow sorted in the absence of blocking antibodies showing T cell-HRS cell rosettes. (e) A CHL case ﬂow sorted in
the absence of blocking antibodies. ( c  2006 American Society of Clinical Pathology [9]).
Flow cytometry oﬀers several potential beneﬁts in the
diagnosis of CHL. These include: (1) increased diagnostic
certainty in cases which may be equivocal or possibly
negative by initial morphologic review; our study identiﬁed
four such cases, which were subsequently conﬁrmed by
extensive immunohistochemical panels or tissue section
morphology on a subsequent biopsy; (2) rapid turn around
time (hours compared to days) required for conﬁrmation
of CHL by immunohistochemistry; and (3) signiﬁcant cost
savings compared to extensive immunohistochemical panels
that have become common in the morphologic diagnosis of
CHL.
Therearestillseveralsigniﬁcantlimitationsofthistesting
strategy. So far, ﬂow cytometry data has been produced by
a single institution and clinical validation at other centers
would be necessary before widespread adoption of this
method for routine clinical use. Our initial validation of
clinical testing for CHL has relied on a 9-color tube. The
instruments that are required for such detection are still
not widely used in most clinical cytometry laboratories.
However, they are commercially available and oﬀer multiple
advantages for other clinical applications. We are now in the
process of validating a six-color assay that will allow more
laboratoriestousethemethodology. Currently,thedetection
of HRS cells is limited to tissue samples and has not been
validatedineitherperipheralbloodorbonemarrowsamples.
Finally, in cases where the immunophenotype of the cells
is consistent with CHL, other related neoplasms must still
remain on the diﬀerential diagnosis. These include cases of
so-called grey zone lymphoma with features intermediate
between classical Hodgkin lymphoma and B cell lymphoma
as well as other B and T cell lymphomas with HRS-like
cells. In the case of grey zone lymphoma, which may
present with sheet-like proliferation of HRS-like cells, an
important observation is the signiﬁcantly increased number
of malignant cells detected by ﬂow cytometry. In cases of
otherBandTcelllymphomas,routineﬂowcytometrypanels
for B and T cells are usually suﬃcient to exclude these
possibilities. In our practice, we have encountered several
such cases following initial validation. These included HRS-
like cells in a case of angioimmunoblastic T cell lymphoma,
that showed an HRS cell population and aberrant T cell
population by ﬂow cytometry and two cases of chronic lym-
phocytic leukemia/small lymphocytic lymphoma (CLL/SLL)4 Advances in Hematology
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Figure 2: Clinical cases of CHL can demonstrate varying proportions of HRS cells rosetted by CD5+ T cells that also increase the apparent
CD45 expression level of the rosetted HRS cells. Representative examples of ﬂow cytometric immunophenotyping of lymph nodes involved
by CHL using the single tube, 9-color assay are shown. HRS cells (shown in red and emphasized) are identiﬁed by their expression of CD30,
CD40, CD95, absence of expression of CD64, and increased side light scatter (SSC-H) compared to normal lymphocytes; all remaining
viable events are in blue. Oblique and horizontal arrows denote rosetted and unrosetted HRS populations, respectively. Dot plots at the
end of panels demonstrate HRS cells in isolation for clarity. (a) Neoplastic unrosetted HRS cells have expression of low CD45, intermediate
CD30, and bright CD40 and CD95, without expression of CD64 (position of negative determined by isotype-matched control experiment,
data not shown), CD5, CD15 (data not shown), or CD20 (data not shown). The small, T-rosetted population of HRS has increased CD45
and expression of CD5 (oblique arrow). (b) Neoplastic unrosetted HRS cells have expression of intermediate CD45, intermediate to bright
CD30, CD40 (data not shown) and CD95 (data not shown), and intermediate CD15, without expression of CD5, CD64, or CD20. The small
rosetted population has expression of CD5 and increased CD45. (c) Neoplastic unrosetted HRS cells have expression of low to intermediate
CD45, variable intermediate to bright CD30, bright CD40 (data not shown) and CD95, intermediate CD15, and variable CD71 (data not
shown), without expression of CD5, CD64, or CD20 (data not shown). The rosetted population has increased CD45 and expression of CD5.
( c  Modiﬁed from 2009 American Society of Clinical Pathology [10]).
with HRS-like cells that both demonstrated a predominant
abnormal CD5+ B cell populations in addition to HRS-
cell populations. While in none of the cases did ﬂow
cytometry provide a misleading diagnosis, the occurrence of
cells with HRS-like phenotype in non-Hodgkin lymphomas
further highlights the necessity of morphologic and ﬂow
cytometric correlation as a part of complete clinical evalu-
ation.
3.Study of Inﬂammatory Backgroundas an
Ancillary Diagnostic Test
A majority of the cellularity in CHL tumors is composed
of an inﬂammatory background. Thus, it is not surprising
that a signiﬁcant amount of eﬀort has been placed in devel-
oping diagnostically useful ﬂow cytometric tests focused on
evaluation of various subsets of inﬂammatory cells. T cellsAdvances in Hematology 5
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Figure 3: Identiﬁcation of a small HRS population in a clinical sample: malignant HRS cells shown in red have increased forward scatter
area (FSC-A) and height (FSC-H) (note a subpopulation with HRS cells with disproportionately increased FSC-A likely corresponding to a
rosetted population) and increased side scatter height (SSC-H) compared to the rest of the node cellularity (blue). The population showed
bimodal, but mostly bright, expression of CD45, low levels of a B cell-marker CD20, no signiﬁcant expression of a monocyte-marker CD64
(mild increase in apparent CD64 expression is due to autoﬂuorescence of the HRS cells, which was previously veriﬁed by isotype control,
data not shown), bright CD30, mostly bright CD5 (with a noticeable nonrosetted CD5 low to negative population), bright CD15 at a level
slightly lower than granulocytes, and bright CD71 (transferrin receptor) consistent with high metabolic activity. Finally, the population
shows a tight cluster in multiple projections including CD95 (bright) versus CD40. In this case, the HRS population represented 0.09% of
the total white cells in the lymph node. The case was morphologically conﬁrmed as CHL-nodular sclerosis type.
have been of particular interest because of the variety of
immunophenotypicallydistinctsubsetsthatcanbeanalyzed.
Some, but not all, reports note increased ratios of CD4 to
CD8-positive T cells in CHL, compared to reactive lymph
nodes by either ﬂow cytometry or immunohistochemistry
[13–15]. An increase in T regulatory cells with a CD4,
CD25, CD152, and FoxP3 immunophenotype has been
identiﬁed in multiple studies by either ﬂow cytometry or
immunohistochemistry [15–18]. Similar populations were
also increased in the blood of many patients with CHL
[19]. Additionally, a recent investigation has demonstrated
a signiﬁcantly increased proportion of CD4+ and CD26−
T cells in CHL compared to reactive nodes with follicular
hyperplasia [20]. These cells possessed both characteristics
of T regulatory cells and recently discovered immunomod-
ulatory Th17 cells by cytokine proﬁling. As T regulatory
cells have prominent roles in suppressing cytotoxic immune
responses, these ﬁndings raise intriguing questions about the
cellular milieu that supports the growth of HRS cells and
protects them from immune mediated demise.
Additional subsets of CD4- and CD8-positive T cells
showing overexpression of CD7 have recently been demon-
strated in CHL [21]. Other antigens including CD2, CD5,
and CD45 were also increased on the CD4-positive T cells,
and CD5 and CD45 were increased on CD8-positive T
cells [21, 22]. The increased expression of CD7 and CD45
on the CD4-positive T cells in particular was seen in
morphologically involved, but not in the morphologically
uninvolved, lymph nodes of the patients with CHL who
had multiple biopsies, suggesting a role for the local intra-
tumoral milieu on the diﬀerentiation of this subset [22].
Figure 4 shows a representative example of a distinct CD4-
positive subset with increased CD2, CD3, CD5, CD7, and
CD45 in a case of CHL.
The role of this subset and its relationship to Th17 or T
regulatory subsets is unclear. While prospective data on the
use of these subsets in diagnostic workup of CHL has not
been reported, retrospective data showed the sensitivity of
approximately 70% and speciﬁcity of 90% in the data set
assembled by Seegmiller and colleagues [21]. Thus, the iden-
tiﬁcation of either increased numbers of T regulatory cells
or CD4-positive T cells with CD7 and CD45 overexpression
may serve as a useful adjunct or screening test for CHL in the
proper clinical context.
4.FlowCytometricIsolationofHRSCells
In addition to clinical detection of HRS cells as an adjunct
test for CHL diagnosis, ﬂow cytometry oﬀers a signiﬁcant
opportunity to advance research investigations into this
poorlyunderstooddisease.Untilrecently,theonlyapplicable
methods for cell enrichment were laser capture microdis-
section of individual HRS cells from tissue sections and
magnetic bead-based enrichment using anti-CD30 antibody
linked beads. While laser capture microdissection allows for6 Advances in Hematology
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Figure 4: (a) CHL reactive background T cells often demonstrate a range of speciﬁc reactive features including increased levels of CD2,
CD5, CD7, and CD45 that are particularly noticeable on the CD4-positive T cells (red) compared to CD8-positive T cells (green). Also note
increased CD4:CD8 ratio among the T cells that is often, but not always, observed in CHL cases. (b) No such changes are seen in a patient
with reactive follicular hyperplasia.
limited molecular analysis, it possesses multiple disadvan-
tages compared to ﬂow cytometric cell sorting including
limiting numbers of cells that can be reasonably isolated,
unpredictable levels of contamination from underlying reac-
tive cells in the section, and the impossibility of obtaining
viable tumor cells. The use of anti-CD30 antibody linked
beads has also been described, but the purity of the enriched
population from many cases is limiting for even molecular
analysis [8]. Flow cytometric sorting, on the other hand,
allows for rapid isolation of thousands of viable HRS cells
from a single case at purities of 90–95%. Populations of even
greater purity, albeit with some loss of yield, can be obtained
by two rounds of cell sorting. This technique provides the
opportunity to deﬁne in vitro growth conditions for HRS
cells that may allow for tissue culture-based manipulation. A
relatively clean separation of HRS cells from inﬂammatory
background also allows for comparative molecular studies
between HRS cells and the inﬂammatory cells from within
the tumor. In one recent example, a loss of heterozygosity
of Kelch midbody protein associated with familial CHL was
also demonstrated in sporadic CHL using comparison to
intratumor T cells [23]. Other applications surely will follow.
5.FlowCytometryforNodularLymphocyte
PredominantHodgkin Lymphoma (NLPHL)
W h i l em a j o rs t r i d e sh a v eb e e nm a d ei nﬂ o wc y t o m e t r i c
detection of CHL, relatively little is known about nodular
lymphocyte predominant Hodgkin lymphoma. CHL and
NLPHL share similar frequency of large malignant cells in an
inﬂammatory background, but unlike CHL, the malignant
cells in NLPHL are generally negative for CD30 and CD15
and express the usual B cell-markers CD20 and CD19 as
well as normal levels of panhematopoietic marker CD45
[5]. These features make these cells harder to distinguish
from nonneoplastic B cells or from neoplastic cells in other
B cell lymphomas within an uncharacterized sample. The
development of clinically useful testing to directly detect
neoplastic cells will require further evaluation of more
sensitive and speciﬁc markers.
Other clues to the diagnosis may come from analyzing
the patterns of the inﬂammatory cell background that
accompanies the tumors. A recent publication demonstrated
that detection of signiﬁcant proportions of CD4 and CD8
double-positive T cells may suggest a diagnosis of NLPHL by
ﬂow cytometry [24]. This study showed that many cases of
NLPHL show T cells having CD4 expression at normal levels
and variable, usually low level of CD8 [24]. Approximately
half the cases of NLPHL demonstrated increases in this
unusual cell population. These populations were infrequent
in CHL and nodular hyperplasia but could be appreciated
in a signiﬁcant proportion of reactive lymph nodes showing
progressive transformation of germinal centers (PTGC)
and in TCRLBCL. These ﬁndings are intriguing as PTGC
[5, 25]a n dT C R L B C L[ 26] are frequently considered to
be related to NLPHL as a possible precursor lesion and
a transformation pathway, respectively. Finally, cells with
similar immunophenotype have been shown to express a
senescence marker CD57 [27] and may correspond to CD57-
positive T cells that are commonly increased in NLPHL and
sometimes observed rosetting the neoplastic cells [28–30].Advances in Hematology 7
Unfortunately, the relatively low sensitivity and speciﬁcity of
ﬁnding a CD4- and CD8-positive T cell population seems to
preclude this analysis from being widely useful diagnostically
at this time.
6. Future Directions and New Findings in Flow
CytometricAnalysisof Hodgkin Lymphoma
While HRS cells with their distinctive immunophenotype
can now be readily identiﬁed and isolated from CHL tumors,
the question remains as to whether these cells represent
the only malignant component or whether some other, less
distinct subset of cells, may serve as a reservoir that gives rise
to these cells. This question is not trivial as it may well aﬀect
development of targeted therapies for CHL, monitoring of
the disease, and our understanding of its pathogenesis. A
recent article has demonstrated that in patients with CHL, a
rare subset of peripheral blood-based B cells carries the same
clonal B cell rearrangement as HRS cells within the tumor
[31]. The authors postulated that these CD27+ Aldehyde
dehydrogenase-positive B cells serve as the stem cells of
Hodgkin lymphoma. A possibly related population of cells
that possesses the ability to actively eﬄux the DNA-binding
dye Hoechst 3341 has also been reported [32]. This ﬁnding
is of importance as such populations are enriched in tissue
speciﬁc stem cells and may serve as progenitor cells in other
neoplasms [33–51]. Further data is certainly required for
evaluation of the clinical signiﬁcance of these very intriguing
ﬁndings. If these cells do represent CHL precursor cells, their
detection in the setting of treatment may be of paramount
importance in monitoring clinical response and designing
new therapies and may be important for prognosis of the
disease.
We hypothesize that ﬂow cytometry could also be
successfully applied to prognostication of clinical outcome
of Hodgkin lymphoma. Several recent studies that used
either immunohistochemistry or molecular expression array
proﬁling have demonstrated that speciﬁc patterns of the
inﬂammatory milieu or antigen expression in HRS cells
themselves correlate with prognosis in CHL. However,
tissue-based antibody staining studies are very diﬃcult to
reproducibly apply in the clinic due to the at best semi-
quantitative nature of staining assessment in tissue sections.
Webelievethatmostofthemarkerscouldbereadilyportable
to a more rapid and quantitative ﬂow cytometry-based
method. In particular, expression of Bcl-2 on the HRS cells
has been shown to be a marker of poor prognosis [52, 53].
Additional markers such as CD20 expression on HRS cells
have also been identiﬁed in some studies as a sign of either
poor [54, 55] (Blood. 1999; 94:598a) or better prognosis
[53, 56]. Both Bcl-2 and CD20 expression can be readily
assessed on HRS cells by ﬂow cytometry.
Similar techniques could be applied for the assessment
of the tumor microenvironment-based predictive markers.
Expression of markers on various cell subsets within the
microenvironment and composition of the inﬂammatory
background have been strongly linked to CHL prognosis
[53, 57–62]. A recent publication has used the frequency
of CD68-positive macrophages within the tumor milieu
to deﬁne subgroups with excellent and poor prognosis
[63]. These studies suggest that it may be possible to
identify patients at greater risk for worse outcome based
on expression of antigens by HRS cells themselves or the
composition of the tumor milieu. Flow cytometry may well
serve as a bridge to bring these exciting research ﬁndings into
routine clinical practice.
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